p53 Overexpression in myeloid leukemic disorders is associated with increased apoptosis of hematopoietic marrow cells and ineffective hematopoiesis

Modern Pathology

Volumn 9, Issue 1, 1996, Pages 48-52

  Orazi, Attilio ^a,b   Kahsai, Mesfin ^a   John, Karla ^a   Neiman, Richard S ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Acute myeloid leukemia; Apoptosis; In situ end labeling; Myelodysplastic syndromes; p53

Indexed keywords

PROTEIN P53;

APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESISTANCE; GENE EXPRESSION; HEMATOPOIESIS; HUMAN; HUMAN TISSUE; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; BONE MARROW; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOID; MIDDLE AGED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030022771     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Crawford L: The 53,000-dalton cellular protein and its role in transformation. Int Rev Exp Pathol 25:1, 1983
2. Lane DP, Crawford L: T antigen is bound to a host protein in SV40 transformed cells. Nature 278:261, 1979
3. Eliyahu D, Raz A, Gruss P, Givol D, Oren M: Participation of p53 cellular tumor antigen in transformation of normal embryonic cells. Nature 312:646, 1984
4. Baker SJ, Markowitz S, Fearon ER, Wilson JKV, Vogelstein B: Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249:912, 1990
5. Finlay CA, Hinds PW, Levine AJ: The p53 proto-oncogene can act as a suppressor of transformation. Cell 57:1083, 1989
6. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M: Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature 352:345, 1991
7. Nigro JM, Baker SJ, Preisinger AC, et al.: Mutations in the p53 gene occur in diverse human tumor types. Nature 342:705, 1989
8. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 253:49, 1991
9. Fenaux P, Preudhomme C, Quiquandon I, et al.: Mutations of the p53 gene in acute myeloid leukemia. Br J Haematol 80:178, 1992
10. Jonveaux P, Fenaux P, Quiquandon I, et al.: Mutations in the p53 gene in myelodysplastic syndromes. Oncogene 6:2243, 1991
11. Orazi A, Cattoretti G, Heerema NA, Sozzi G, John K, Neiman RS: Frequent p53 over-expression in therapy related myelodysplastic syndromes and acute myeloid leukemias: An immunohistochemical study of bone marrow biopsies. Mod Pathol 6:521, 1993
12. Bennett JM, Catovsky D, Daniel MT, et al.: Proposals for the classification of the acute leukemias (FAB co-operative group). Br J Haematol 33:451, 1976
13. Bennett JM, Catovsky D, Daniel MT, et al.: Proposals for the classification of the myelodysplastic syndromes. The French-American-British co-operative group. Br J Haematol 51:189, 1982
14. Clark DM, Lampert IA: Apoptosis is a common histopathological finding in myelodysplasia: The correlate of ineffective haematopoiesis. Leuk Lymphoma 2:415, 1990
15. Hatfill SJ, Fester ED, Steytler JG: Apoptotic megakaryocyte dysplasia in the myelodysplastic syndromes. Hematol Pathol 6:87, 1992
16. Yoshida Y: Hypothesis: Apoptosis may be the mechanism responsible for the premature intramedullary cell death in the myelodysplastic syndrome. Leukemia 7:144, 1993
17. Raza A, Mundle V, Iftikhar A, et al.: Simultaneous assessment of cell kinetics and programmed cell death in bone marrow biopsies of myelodysplastics reveals extensive apoptosis as the probable basis for ineffective hematopoiesis. Am J Hematol 48:143, 1995
18. Greenberg PL, Ginzton N, Rajapaksa R: Oncoprotein expression and apoptosis in myelodysplastic syndrome (MDS) marrow cells (abstract). Blood 84:54a (supp 1), 1994
19. Schmitz GG, Walter T, Seibl R, Kessler C: Nonradioactive labeling of oligonucleotides in vitro with the hapten digoxigenin by tailing with terminal transferase. Anal Biochem 222:1991, 192
20. Gavrieli Y, Sherman Y, Ben-Sasson SA: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119:493, 1992
21. Wijsman JH, Jonker RR, Keijzer R, Van De Velde CJH, Cornelisse CJ, Van Dierendonck JH: A new method to detect apoptosis in paraffin sections: In situ end-labeling of fragmented DNA. J Histochem Cytochem 41:7, 1993
22. Gao X, Mundle S, Alvi S, et al.: DNA laddering and in situ end labeling (ISEL) of fragmented DNA simultaneously demonstrate high apoptosis in myelodysplastic syndromes (MDS) but low in acute myeloid leukemia (AML) (abstract). Blood 84:605a (supp 1), 1994
23. Shi S-R, Key ME, Kalra KL: Antigen retrival in formalin-fixed, paraffin-embedded tissues: An enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 39:741, 1991
24. Kerr JFR, Wyllie AH, Currie AR: Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26:239, 1972
25. Wyllie AH, Kerr JFR, Currie AR: Cell death: The significance of apoptosis. Int Rev Cytol 68:251, 1980
26. Wyllie AH, Beattie GJ, Hargreaves AD: Chromatin changes in apoptosis. Histochem J 13:681, 1981
27. Walker NI, Harmon BV, Gobé GC, Kerr JFR: Patterns of cell death. Methods Achiev Exp Pathol 13:18, 1988
28. Wyllie AH: Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 284:555, 1980
29. Sozzi G, Miozzo M, Orazi A, et al.: Cytogenetic study in therapy-related myelodysplastic syndromes (t-MDS) and acute non-lymphocytic leukemia (t-ANLL). Br J Cancer 61:425, 1990
30. Orazi A, Cattoretti G, Soligo D, Luksch R, Lambertenghi- Deliliers G: Therapy-related myelodysplastic syndromes: Prognostic implications of FAB classification, bone marrow histology and immunohistology. Leukemia 7:838, 1993
31. Lane DP: Mutation of the p53 gene and accumulation of the p53 protein: Common steps found in the majority of human cancers. In Accomplishments in Cancer Research, 1990 prize year, edited by Fortner JG, Rhoads JE, p 252 Philadelphia, J.B. Lippincott, 1991
32. Prokocimer M, Rotter V: Structure and function of p53 in normal cells and their aberrations in cancer cells: Projection on the hematopoietic cell lineages. Blood 84:2391, 1994
33. Fenaux P, Jonveaux P, Quiquandon I, et al.: p53 gene mutations in acute myeloid leukemia with 17p monosomy. Blood 78:1652, 1991
34. 2 gene, a regulator of p53 function, in myelodysplastic syndromes. Leukemia 7:1291, 1993
35. Imamura J, Miyoshi I, Koeffler HP: p53 in hematologic malignancies. Blood 84:2412, 1994